Drug Profile


Alternative Names: TolerMab Anti-CD8 monoclonal antibody; TRX2 antibody - TolerRx

Latest Information Update: 01 Sep 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TolerRx
  • Class Monoclonal antibodies
  • Mechanism of Action CD8 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Leukaemia; Transplant rejection

Most Recent Events

  • 01 Sep 2005 Discontinued - Preclinical for Leukaemia in USA (unspecified route)
  • 01 Sep 2005 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
  • 26 Aug 2002 Preclinical trials in Leukaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top